Kaiku Health Parent: Elekta
Kaiku Health has developed a digital health intervention platform classified as a Medical Device in cancer care. Its algorithms screen symptoms, notify care teams and provide personalized support for patients. Kaiku Health has modules for over 25 cancer types across different cancer care pathways, enabling cancer clinics to provide optimized care through timely symptom management and improved workflow. In May 2020, Kaiku Health was acquired by Sweden's Elekta - a global leader in radiotherapy solutions to fight cancer and neurological disease.
Select partners: Novartis, Roche, MSD Germany, Netherlands Cancer Institute, Hirslanden Radiotherapy, Amgen, UCLA Anderson School of Management.
Diseases & Conditions Cancer
Funding π°
Select investors Debiopharm Innovation Fund, Tesi, Reaktor Ventures, Prodeko Ventures
Key people π§βπ€βπ§
- Lauri Sippola - Co-founder & CEO
- Henri Virtanen - Co-founder, Chief Product Officer & Deputy General Manager
- M.D. Vesa Kataja - Chief Medical Officer
- Katariina Kronholm - Chief Commercial Officer
- Pauli Parkkinen - VP Engineering
- Reetta Arokoski - VP Customer Success & Operations
- Martin Deppe - VP Product
Highlights β
- Works with all common cancer types: Kaiku Health is used for capturing and processing data in all common cancer types, including breast cancer, prostate and other urological cancers, lung cancer, colorectal and other GI cancers, hematologic cancers, melanoma and other skin cancers, gynecological cancers, head and neck cancers.
- Proven to work: In March 2023, the study's results showed that Kaiku Health digital patient monitoring enhances the early detection of evolving peripheral sensory neuropathy and reduces phone call burden. π
- Used across 3 continents: As of May 2023, Kaiku's platform is in clinical routine use in over 75 cancer clinics and hospitals in Europe as well as North and South America.
Video βΆοΈ
Awards & Recognitions π
Quotes π¬
“
We are excited about the impact digital technologies will have on the patient journey and are particularly enthusiastic to help take the digital therapeutic approach in oncology out of the lab and onto the market where the benefits of this high frequency monitoring can be expected to bring real outcomes improvement.
— Tanja Dowe, CEO at Debiopharm Innovation Fund π
“
We have studied the Finnish digital health sector thoroughly and found it extremely interesting from an investor's point of view. The Kaiku Health team impressed us with its strong technological know-how, for instance in the use of artificial intelligence. Kaiku Health has strong international customer references and a broad user-base for a young health-tech company.
— Joni Karsikas, Investment Manager at Tesi π
Last update: May 9, 2023
Disclaimer: We can not guarantee that the information on this page is 100% correct. more